Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
Objectives: To investigate the subjective assessments of an antipsychotic treatment with brexpiprazole. Methods: This was a 14-week prospective observational study. Nineteen patients participated in the study between February 2019 and January 2020. Results: Patients had a mean age of 40.6±14.2...
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
Fujita Medical Society
2023-08-01
|
| Serija: | Fujita Medical Journal |
| Teme: | |
| Online pristup: | https://www.jstage.jst.go.jp/article/fmj/9/3/9_2022-031/_pdf/-char/en |
| _version_ | 1827889036015960064 |
|---|---|
| author | Rina Yokoi Masakazu Hatano Hiroyuki Kamei Aoi Morita Manako Hanya Nakao Iwata Shigeki Yamada |
| author_facet | Rina Yokoi Masakazu Hatano Hiroyuki Kamei Aoi Morita Manako Hanya Nakao Iwata Shigeki Yamada |
| author_sort | Rina Yokoi |
| collection | DOAJ |
| description | Objectives: To investigate the subjective assessments of an antipsychotic treatment with brexpiprazole.
Methods: This was a 14-week prospective observational study. Nineteen patients participated in the study between February 2019 and January 2020.
Results: Patients had a mean age of 40.6±14.2 years and a Clinical Global Impressions-Severity of Illness scale (CGI-S) score of 4.6±1.2 at the initiation of brexpiprazole treatment. The Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) total score significantly improved from 68.1±22.3 in week 2 to 79.5±21.0 in week 14 (p=0.0084). The SWNS-J subscales of self-control and social integration status also significantly improved from 14.0±4.7 and 13.9±6.0 in week 2 to 17.0±4.7 and 16.0±5.1 in week 14, respectively (p=0.0053 and 0.012, respectively). No significant improvements were observed in any other SWNS-J subscales or the Drug Attitude Inventory-10 (DAI-10) in the 14-week observation period. Moreover, the SWNS-J total score did not correlate with the DAI-10 (r=0.31, p=0.19), or CGI-S (r=–0.18, p=0.47) scores.
Conclusions: The present results suggest that brexpiprazole might improve subjective well-being, although this may not necessarily reflect psychopathological improvements. To enhance medication adherence, it is important to perform subjective assessments on patients over time. |
| first_indexed | 2024-03-12T20:49:24Z |
| format | Article |
| id | doaj.art-9a0de0d007e440e9b565ff158b453a9c |
| institution | Directory Open Access Journal |
| issn | 2189-7247 2189-7255 |
| language | English |
| last_indexed | 2024-03-12T20:49:24Z |
| publishDate | 2023-08-01 |
| publisher | Fujita Medical Society |
| record_format | Article |
| series | Fujita Medical Journal |
| spelling | doaj.art-9a0de0d007e440e9b565ff158b453a9c2023-08-01T05:38:59ZengFujita Medical SocietyFujita Medical Journal2189-72472189-72552023-08-019323123510.20407/fmj.2022-031Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational studyRina Yokoi0Masakazu Hatano1Hiroyuki Kamei2Aoi Morita3Manako Hanya4Nakao Iwata5Shigeki Yamada6Department of Pharmacotherapeutics and Informatics, Fujita Health University, School of Medicine; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo UniversityDepartment of Pharmacotherapeutics and Informatics, Fujita Health University, School of Medicine; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University; Department of Psychiatry, Fujita Health University, School of MedicineOffice of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University; Department of Psychiatry, Fujita Health University, School of MedicineDepartment of Pharmacotherapeutics and Informatics, Fujita Health University, School of Medicine; Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo UniversityOffice of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo UniversityDepartment of Psychiatry, Fujita Health University, School of MedicineDepartment of Pharmacotherapeutics and Informatics, Fujita Health University, School of MedicineObjectives: To investigate the subjective assessments of an antipsychotic treatment with brexpiprazole. Methods: This was a 14-week prospective observational study. Nineteen patients participated in the study between February 2019 and January 2020. Results: Patients had a mean age of 40.6±14.2 years and a Clinical Global Impressions-Severity of Illness scale (CGI-S) score of 4.6±1.2 at the initiation of brexpiprazole treatment. The Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) total score significantly improved from 68.1±22.3 in week 2 to 79.5±21.0 in week 14 (p=0.0084). The SWNS-J subscales of self-control and social integration status also significantly improved from 14.0±4.7 and 13.9±6.0 in week 2 to 17.0±4.7 and 16.0±5.1 in week 14, respectively (p=0.0053 and 0.012, respectively). No significant improvements were observed in any other SWNS-J subscales or the Drug Attitude Inventory-10 (DAI-10) in the 14-week observation period. Moreover, the SWNS-J total score did not correlate with the DAI-10 (r=0.31, p=0.19), or CGI-S (r=–0.18, p=0.47) scores. Conclusions: The present results suggest that brexpiprazole might improve subjective well-being, although this may not necessarily reflect psychopathological improvements. To enhance medication adherence, it is important to perform subjective assessments on patients over time.https://www.jstage.jst.go.jp/article/fmj/9/3/9_2022-031/_pdf/-char/ensubjective well-beingdrug attitudebrexpiprazoleantipsychotic agentsschizophrenia |
| spellingShingle | Rina Yokoi Masakazu Hatano Hiroyuki Kamei Aoi Morita Manako Hanya Nakao Iwata Shigeki Yamada Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study Fujita Medical Journal subjective well-being drug attitude brexpiprazole antipsychotic agents schizophrenia |
| title | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
| title_full | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
| title_fullStr | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
| title_full_unstemmed | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
| title_short | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
| title_sort | subjective assessment of brexpiprazole in patients with schizophrenia a prospective observational study |
| topic | subjective well-being drug attitude brexpiprazole antipsychotic agents schizophrenia |
| url | https://www.jstage.jst.go.jp/article/fmj/9/3/9_2022-031/_pdf/-char/en |
| work_keys_str_mv | AT rinayokoi subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT masakazuhatano subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT hiroyukikamei subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT aoimorita subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT manakohanya subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT nakaoiwata subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT shigekiyamada subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy |